AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses

AIM ImmunoTech Inc AIM has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses.
The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).
This antiviral study will be conducted by hVIVO, a subsidiary of Open Orphan plc.
The AIM-sponsored study is expected to start in Q4 2021.
AIM submitted a proposed protocol for the study to the Oxford Research Ethics Committee/Medicines and Healthcare Regulatory Agency.
The committee met last week, and its response is expected by mid-November.
Phase 2a HCT will enroll 64 participants.
Related: AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease.
Price Action: AIM stock is up 1.54% at $1.98 during the premarket session on the last check Thursday.

Momentum99.75

GrowthNot Available

QualityNot Available

Value9.09

Short

Medium

Long